Get informed when a big investor buys or sells
+ Follow-32.46%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Xencor (XNCR) currently reports a ROE of -32.46%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Xencor's ROE history and peer comparisons.
Xencor's ROE of -32.46% is higher than the Healthcare sector average of -75.84%. That is roughly 57.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Xencor's current -32.46% should be judged against Healthcare norms (sector average: -75.84%) and against XNCR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -32.46%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Xencor, and consider following XNCR for alerts when major investors trade the stock.
Xencor is classified in the Healthcare sector. On ROE, it currently shows -32.46% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XNCR with unrelated industries.